Field trials of a gonococcal vaccine.
Several small, well controlled field trials with a gonococcus vaccine have been initiated. The results to date indicate that the vaccine elicits only mild reactions in humans, and that it will produce antibodies of possible significance in over 90 per cent of vaccines. Its value in preventing gonorrhea has yet to be established. Studies towards this end are now being considered.
D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000032:analysis; D000917:Antibody Formation; D001428:Bacterial Vaccines / Q000009:adverse effects; D002986:Clinical Trials as Topic; D005260:Female; D005334:Fever / Q000209:etiology; D006069:Gonorrhea / Q000517:prevention & control*; D006801:Humans; D008297:Male; D013997:Time Factors; D014611:Vaccination / Q000009:adverse effects
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines